vTv Therapeutics Inc. (VTVT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue TTM

0 15M 30M 45M Q3 '21: 10.4M Q4 '21: 4M Q1 '22: 5M Q2 '22: 5M Q3 '22: 2M Q4 '22: 2M Q1 '23: 18K Q2 '23: 9K Q3 '23: 9K Q4 '23: 0 Q1 '24: 1M Q2 '24: 1M Q3 '24: 1M Q4 '24: 1M Q1 '25: 17K Q2 '25: 17K Q3 '25: 17K Q4 '25: 0 Q1 '26: 36.8M Q2 '26: 36.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-45M -30M -15M 0 15M 30M 45M Q3 '21: -8.7M Q4 '21: -21.7M Q1 '22: -23.9M Q2 '22: -23.2M Q3 '22: -27.3M Q4 '22: -22.5M Q1 '23: -23.5M Q2 '23: -27.5M Q3 '23: -27.1M Q4 '23: -25.5M Q1 '24: -23.7M Q2 '24: -22.9M Q3 '24: -24M Q4 '24: -24.2M Q1 '25: -25.1M Q2 '25: -25.6M Q3 '25: -29.8M Q4 '25: -32.8M Q1 '26: -3M Q2 '26: -9.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-30M -20M -10M 0 10M 20M 30M Q3 '21: -4.8M Q4 '21: -13M Q1 '22: -15.8M Q2 '22: -18.3M Q3 '22: -21.5M Q4 '22: -19.2M Q1 '23: -16.7M Q2 '23: -19.1M Q3 '23: -21.5M Q4 '23: -20.2M Q1 '24: -20.6M Q2 '24: -20.2M Q3 '24: -18.3M Q4 '24: -18.5M Q1 '25: -18.7M Q2 '25: -19.6M Q3 '25: -23.5M Q4 '25: -27M Q1 '26: 2.3M Q2 '26: -4.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-30M -20M -10M 0 10M 20M 30M Q3 '21: -15.1M Q4 '21: -19.3M Q1 '22: -15M Q2 '22: -10.3M Q3 '22: -15.6M Q4 '22: -16M Q1 '23: -20.2M Q2 '23: -27M Q3 '23: -23M Q4 '23: -19.1M Q1 '24: -21.2M Q2 '24: -21.8M Q3 '24: -23.4M Q4 '24: -25.3M Q1 '25: -23.7M Q2 '25: -22M Q3 '25: -20.8M Q4 '25: -25.3M Q1 '26: -10.4M Q2 '26: -16.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-60M -40M -20M 0 20M 40M 60M Q4 '15: -37M Q2 '17: -50.6M Q3 '17: -49.7M Q4 '17: -44.6M Q4 '15 Q2 '17 Q3 '17 Q4 '17

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

EPS TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.